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1. Introduction  
In the last two decades relevant improvements have been achieved in cancer therapy with a 
significant increase in overall survival. However these achievements have also been 
accompanied by a rise in the occurrence of side effects involving several organs, in 
particular the cardiovascular system. Indeed, the incidence of cardiotoxicity is continuously 
growing which can vanish the effectiveness of cancer therapy.  
Breast cancer is the second most common form of cancer in women and the leading cause of 
death caused by malignancy. Over the past 25 years, breast cancer incidence has risen 
globally, with the highest rates in industrialized countries. However, the survival rate of 
cancer patients has greatly increased because of early detection through screening, as well as 
improvement in pharmacologic treatment. Women are, therefore, now living sufficiently 
long for delayed consequences of treatment to become increasingly evident. 
Approximately 20-25% of breast cancer overexpresses the human epidermal growth factor 
receptor II (HER-2). Amplification of HER-2 gene confers aggressive behavioral traits on 
breast cancer cells, including incresead growth and proliferation, enhanced invasiveness 
and metastatic capability. (Slamon, 1987) 
HER-2 is a transmembrane tyrosine kinase receptor and a member of the epidermal growth 
factor receptor (EGFR) family,and regulate many important cell-type specific functions, 
particularly cell growth, proliferation and survival. (Slamon, 1987; Chien, 2006)  
The use of trastuzumab (a humanized monoclonal antibody against HER-2 receptor) has 
changed the natural history of patients with HER-2 positive breast cancer. In the metastatic 
setting, the combination of trastuzumab plus chemotherapy has significantly improved 
survival, response rate, time to progression, and quality of life when compared with 
standard chemotherapy (Slamon 1987, 2001; Vogel, 2002). In the adjuvant setting, the use of 
trastuzumab decreased the risk of recurrence and death (Buzdar, 2005). Given these 
impressive results, trastuzumab has become the standard of care for treatment of patients 
with HER-2 positive breast cancer.  
Although trastuzumab is devoid of the classical toxicities related with cancer treatment, one 
of major concerns noted is the occurrence of symptomatic and asymptomatic cardiac 
dysfunction. In fact, this treatment showed to be associated with an increased incidence of 
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heart failure that ranged from 4.1% in the adjuvant setting to 27% in patients with metastatic 
disease who received concurrent anthracycline therapy (Perez E., 2004). Early identification 
of patients at risk for cardiotoxicity is a major challenge for both cardiologists and 
oncologists, for the definition of more tailored antineoplastic therapeutic interventions. The 
use of cardiac biomarkers such as BNP, N-terminal pro-BNP, and troponin I, has been 
suggested as a method for early detection of cardiotoxicity. Also, newer measurements of 
LV function such as strain, strain rate and speckle tracking may be sensitive tools to detect 
myocardial dysfunction before changes in EF are evident, possibly identifying at-risk 
patients at an earlier stage. 
2. Diagnosis and strategies 
2.1 Clinical benefits of trastuzumab 
Based in substantial improvement achieved with trastuzumab in the trials performed, US 
Food and Drug Administration approved in 1998 this agent for the treatment of metastatic 
breast cancer. Indeed, in phase 2 trial was found an objective response in 12% of patients. 
(Baselga et al., 1996) These benefits were further confirmed in larger phase 2 and phase 3 
trials (Cobleigh et al., 1999; Slamon et al., 2001). The phase 3 trial was design to compare a 
conventional chemotherapy regime with and without additional trastuzumab treatment. 
The data demonstrated that trastuzumab association to chemotherapy produced substantial 
response rate, improvement in time to disease progression, as well as reduction in 1-year 
mortality. (Slamon et al., 2001) 
Since 2006 the use of trastuzumab has been extended to treat HER-2 positive early breast 
cancer patients. Five major randomized trials (Herceptin Adjuvant trial - HERA, National 
Surgical Adjuvant Breast and Bowel Project - NSABP B-31, North Central Cancer Treatment 
Group - NCCTG N9831, Breast Cancer International Research Group – BCIRG 006 and 
Finland Herceptin trial - FinHer) have proven the benefit of adjuvant trastuzumab in early 
breast cancer patients. More than 11 000 patients were enrolled and treatment with 
trastuzumab led to about 50% improvement in disease-free survival and 33% improvement 
in overall survival. (Romond et al., 2005; Piccart-Gebhart et al., 2005; Tan-Chiu et al., 2005; 
Slamon et al., 2005; Joensuu et al., 2006).  
Thus, concurrent treatment with trastuzumab is actually the standard of care for patients 
with early HER-2 positive breast cancer. 
2.2 What does cardiotoxicity mean? 
A precise definition of cardiotoxicity is still lacking. The Cardiac Review and Evaluation 
Committee supervising trastuzumab trials created a practical and easily applicable 
definition, which considered chemotherapy-induced cardiotoxicity as one or more of the 
following: 1) cardiomyopathy characterized by a decrease in LVEF, either global or more 
severe in the septum; 2) heart failure (HF) symptoms; 3) signs associated with HF, such as S3 
gallop, tachycardia, edema; 4) decline in initial LVEF of at least 5% to less than 55% with 
accompanying signs or symptoms of HF, or asymptomatic decrease in LVEF in the range of 
equal to or greater than 10% to less than 55% (Seidman, 2002). (Table 1) 
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1. Cardiomyopathy characterized by a decrease in LVEF or changes of contraction most 
apparent in the interventricular septum 
2. Heart failure symptoms 
3. Signs associated with heart failure 
4. Decline in initial LVEF of at least 5% to less than 55% with signs and symptoms of 
heart failure or asymptomatic decrease in LVEF of at least 10% to less than 55% 
Adapted from Seidman, et al. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. 
Journal of Clinical Oncology, Vol. 20, pp. 1215 – 1221 
Table 1. Cardiac Review and Evaluation Committee criteria for the diagnosis of cardiac 
dysfunction 
Cardiotoxicity can develop in a subacute, acute, or chronic manner: 
a. Acute or subacute cardiotoxicity develop during the treatment period up to 2 weeks 
after therapy. It is characterized by electrocardiographic abnormalities such as QT-
intervals changes, ventricular repolarization abnormalities, supraventricular and 
ventricular arrhythmias or by acute heart failure, pericarditis, myocarditis or acute 
coronary syndromes.  
b. Chronic cardiotoxicity is the most frequent and feared form. It can be divided in 2 
groups according to the timing of symptoms onset: early, when occur in the first year 
after treatment and late when manifests more than 1 year after chemotherapy. The most 
common feature of chronic cardiotoxicity is asymptomatic systolic left ventricular 
dysfunction that can further lead to congestive HF. The incidence of this type of 
cardiotoxicity depends on several factors such as, total administered dose of 
chemotherapy, time of follow-up, age, history of previous cardiac disease, previous 
mediastinal radiation, as well as on the criteria used for cardiotoxicity assessment, 
ranging in different studies from 5% to 65% of patients. (Dolci, 2008; Pai, 2000). 
The classic example of cardiotoxicity from anticancer treatment is anthracycline-related 
cardiomyopathy that remains the most common cardiotoxic chemotherapy agent. However 
many other agents can cause cardiotoxicity, namely the monoclonal antibody trastuzumab.  
The development of chemotherapy-induced cardiomyopathy has significant implications. It 
has not only a negative impact on the cardiac outcome of cancer patients, but also limits 
their therapeutic options.  
2.3 Prevalence of trastuzumab induced-cardiomyopathy 
Cardiotoxicity was an unexpected finding in the phase 3 trials, as early clinical trials 
provided little or no indication of trastuzumab-induced cardiomyopathy. Although heart 
failure was seen in some patients enrolled in phase 2 trials, the rate of occurrence was low 
and patients were at increased risk due to previous anthracycline treatment. Subsequent 
reports of trastuzumab-related cardiotoxicity in the phase 3 combination chemotherapy 
trials prompted a retrospective analysis of seven phase 2 and 3 trastuzumab trials by an 
independent Cardiac Review and Evaluation Committee (CREC). (Seidman, Hudis, & Pierri, 
2002) An accurate assessment of cardiotoxicity in these trials has proved difficult because 
their design was different in what concerns the number of patients, definition of 
cardiotoxicity, analysis of end points and duration of follow-up. CREC used a new set of 
criteria to define cardiotoxicity (Table 1) and events were also classified by the New York 
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Heart Association (NYHA) functional classification system. Data from 1219 patients enrolled 
in those 7 trials were retrospectively analyzed and cardiotoxicity was detected in 112 
patients (9.2%). The incidence of trastuzumab-induced cardiomyopathy ranged from 1% to 
27% in different arms of trials and was higher when trastuzumab and anthracyclines were 
used concurrently (Seidman, Hudis, & Pierri, 2002)(Table 2) 
 
Adapted from Keefe DL (2002). Trastuzumab-associated cardiotoxicity. Cancer, Vol. 95, pp. 1592-1600 
AC=anthracycline plus cyclophosphamide; CD=cardiac dysfunction; NYHA=New York Heart 
Table 2. Retrospective analysis conducted by the Cardiac Review and Evaluation Committee 
of seven studies to detect trastuzumab-related cardiotoxicity.  
Concerns about cardiotoxicity, together with the remarkable tumor response to this therapy, 
served as an impetus for several large trials collectively known as the trastuzumab adjuvant 
trials, which incorporate appropriate cardiac monitoring (Buzdar,2005; Perez, 2004; Cobleigh, 
1999; Slamon 2001; Romond, 2005). The study protocol in these trials determined baseline 
assessment of LVEF using echocardiogram or myocardial scintigraphy and the exclusion of 
patients with impaired cardiac function, high doses of cumulative anthracycline exposure, and 
previous history of heart disease. Data from these trials are summarized in Table 3. 
 
Adapted form Popat & Smith. (2008). Therapy insight: anthracyclines and trastuzumab – the optimal 
management of cardiotoxic side effects. Nature Clinical Practice, Vol. 5, pp. 324-335 
Table 3. Summary of trastuzumab-induced cardiotoxicity from adjuvant trials.  
In the combined analysis of NCCTG N9831 and NSABP B-31 trials (administration of 
trastuzumab concurrent with adjuvant taxanes after anthracycline chemotherapy), was 
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found that trastuzumab was withdrawal before 52 weeks in 31.4% of patients treated. In 
14.2% of them was due to asymptomatic LVEF decline and in 4.7% due to HF symptoms 
(Romond et al., 2005). The 3-year cumulative incidence of NYHA class III or IV HF or death 
from cardiac causes reported in N9831 trial was 2.9% in the trastuzumab group, compared 
to 0% in the control group. In B-31 trial this endpoint was detected in 4.1% in those treated 
with trastuzumab and 0.8% in the control group. Twenty-seven patients from the total of 31 
women who developed trastuzumab-induced cardiomyopathy, were followed for at least 6 
months and only 1 patient had persistent symptoms of heart failure. (Slamon, 2001) These 
results were subsequently analysed by an independent group of reviewers that constituted 
the Adjuvant Cardiac Review and Evaluation Committee (ACREC) (Seidman, 2002). This 
independent review confirmed earlier risk estimates by showing that the concurrent use of 
trastuzumab and anthracycline based chemotherapy, increased the rate of congestive heart 
failure (CHF) nearly four-fold, from 0.45% to 2.0%, at a median follow-up of 1.9 and 2.0 
years, respectively.  
In HERA trial (Perez, 2004) was reported a smaller number of cardiac events compared with 
B-31 and N9831 studies. This trial is a three-group, randomized trial that compared 1 year or 
2 years of trastuzumab with observation in women with HER-2 positive early breast cancer. 
The overall rate of trastuzumab withdrawal due to safety issues was 6.8%, with 4% stopping 
the treatment due to cardiac issues. The rate of symptomatic CHF was 2% in the 
trastuzumab group and 0.2% in the control group, with NYHA class III or IV CHF occurring 
in 0.6% of patients receiving trastuzumab and 0% of the control group. An asymptomatic or 
mildly symptomatic decline in LVEF was seen in 7.4% of women on trastuzumab and 2.3% 
of controls (Perez, 2004; Seidman, 2002). The overall risk of severe CHF reported in HERA 
was lower than that in B-31 (0.6% versus 4%) as was the proportion of patients who 
discontinued trastuzumab due to cardiac issues. The explanation for these differences is not 
clearly established, but we can speculate that it may be due to the longer interval between 
stopping anthracyclines and initiating trastuzumab or to the inclusion criteria that 
determined a LVEF≥55% in HERA trial compared to 50% for N9831/B-31 trials. 
An aspect of interest in the BCIRG trial is that one arm of this study did not include 
concomitant or sequential therapy with anthracyclines. This fact permitted the assessment of 
the true effect of trastuzumab on the heart without having to adjust for previous 
anthracycline lesion, that otherwise interfere with interpretation of cardiotoxicity. The 
incidence of NYHA class III or class IV CHF was 5.1-fold greater in the anthracycline group 
than in the nonanthracycline arm (1.96% versus 0.38%) and the number of patients with 
LVEF decline of more than 10% from baseline was 19% and 9%, respectively.  
2.4 Mechanism of cardiotoxicity 
Cardiotoxicity came to the forefront of concerns over chemotherapy in the early 1970s, when 
was detected a cumulative dose-related cardiac dysfunction was detected related with 
anthracycline treatment.  
This agent produces a cardiac dysfunction identified as type I, characterized by 
ultrastructural abnormalities, morphological cellular (vacuoles, myofibrillar disarray and 
dropout, necrosis) and heart (dilated cardiomyopathy) changes and subsequent clinical 
evident dysfunction. (Billingham, 1978; Lefrak, 1973; Billingham, 1978) It is dose-related and 
virtually irreversible. Described methods to minimize type I cardiotoxicity include prolonged 
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infusional administration schedules (Legha, 1982) and use of the free-radical scavenger 
dexrazoxane (Swain, 2004). Additionally, liposomal delivery, are being studied liposomal 
delivery systems (Ewer, 2002 ) and less-toxic analogs and less toxic analogs are being study. 
In contrast, type II cardiac dysfunction associated with trastuzumab therapy does not seem 
to cause any ultrastructural change, while a myocardial dysfunction under cardiac stress is 
present. (Ewer, 2005) Other specific features are: it seems not to be dose-related; it increases 
when trastuzumab is given concurrently with anthracyclines; it seems to be reversible; and 
normal cardiac function may be restored with medical management of heart failure 
(Seidman, 2002; Valero, 2004; Perez, 2004; Ewer, 2008). Table 4 compares type I and type II 
chemotherapy-related cardiac dysfunction. 
 
Reprinted from Ewer & Lippman (2005).Type II chemotherapy-related cardiac dysfunction: time to 
recognize a new entity. Journal of Clinical Oncology, Vol. 23, pp. 2900-2902 
Table 4. Chemotherapy-related cardiac dysfunction.  
The mechanisms of type I and type II cardiac dysfunction are complex and distinct. Type I 
cardiotoxicity is due, predominantly to iron-based oxygen free-radical that induce oxidative 
stress on cardiac cells. These free radicals produce peroxidation of myocyte membranes and 
subsequent influx of intracellular calcium, accelerated degradation of key sarcomeric 
protein and disruption of new sarcomere protein synthesis. (Valero, 2004; Ewer, 2002) 
The molecular basis of type II chemotherapy related cardiac dysfunction is beginning to be 
elucidated (Speyer, 2002; Crone, 2002; Ozcelik, 2002; Sawyer, 2002; Negro, 2004). The 
mechanism of trastuzumab induced cardiotoxicity involves, at least in part, the ErbB2 
pathway. This agent binds to the extracellular domain of the HER-2 protein and thus blocks 
ErbB2 signalling required for the growth, repair, and survival of cardiac cells. (Negro, 2004) 
ErbB2 signalling is highly complex, involving multiple ligand classes, cell systems, and 
pathway interactions. Of those actions, activation of the transcription factor nuclear-B (NF-
B) seems to play an important rule. Indeed the NF-B pathway is also involved in cardiac 
cells under stress, such as in myocardial infarction and hypertension and it seems to be 
essential in restoring the reperfusion after ischemia and also in reducing apoptosis. 
(Feldman, 2007). 
Evidence supports a critical role for neuregulin 1 (NRG1) signalling through HER-2/HER-4 
heterodimerization in cardiomyocyte survival pathways and maintenance of function. 
(Sawyer, 2002) NRG1 is produced by cardiac endothelial cells, binds HER-4 on 
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cardiomyocytes and leads to heterodimerization with HER-2, with consequent activation of 
diverse intracellular signalling pathways, such as the PI3-kinase/AKT and MAP kinase 
pathways. Mouse models have given important contributes to these discovers. Mice with 
HER428 and NRG131 knockouts are both embryonically lethal.  
Moreover, the essential role of HER-2 in maintenance of cardiac contractile function and 
structure and the possible protective effect provided by HER-2 was shown in a mouse 
model with a cardiac-restricted conditional HER-2 deletion mutant. Indeed, these mice 
stayed alive, but developed a dilated cardiomyopathy. (Negro, 2004; Crone, 2002; Ozcelik, 
2002) This model provided support to the hypothesis that cardiac lesion related to 
trastuzumab is the result of direct targeting and inhibition of the HER-2 receptor, rather 
than immune-mediated or non-cardiac effects. Additionally, these mice were also sensitized 
to develop an anthracycline-induced cardiac dysfunction reflecting that seen clinically. 
Inhibition of the previous described pathways after an insult such as anthracycline 
treatment could thus interfere with the heart’s repair mechanisms. Indeed, de Kort et al. 
(2007) showed that myocardial HER-2 is upregulated in humans shortly after anthracycline 
exposure, providing support for the vulnerable-window hypothesis. (Fig 1.) 
 
Reprinted from Ewer, M. (2010). Troponin I Provides Insight Into Cardiotoxicity and the Anthracycline-
Trastuzumab Interaction. Journal of Clinical Oncology, Vol. 28, No. 25, pp 3901-3909  
Fig. 1. (A) Simplified flow diagram of myocyte injury after anthracycline administration. 
Cell death is preceded by a period of vulnerability during which cell repair may take place. 
(B) The addition of trastuzumab inhibits cell repair compounding the loss of cardiac 
myocytes. HER2= human epidermal growth factor receptor 2.  
Although inhibition of HER-2 signalling seems to be a central mechanism of trastuzumab-
related cardiomyopathy, the pathophysiologic mechanism is likely more complex. Indeed 
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early clinical results with lapatinib, an oral tyrosine kinase inhibitor, show minimal 
cardiotoxicity. (Geyer, 2006) Actually the explanation for this paradox is not sufficiently 
clear and remains an area of intense investigation. It is suggested that the difference 
between the two drugs may be explained by trastuzumab effect on adenosine triphosphate 
(ATP) depletion. Cardiac cells need an important quantity of ATP molecules and thus an 
agent that interferes with mitochondrial activity has the potential of alter normal myocyte 
function by decreasing the energy source. (Menendez, 2007) The binding between erbB2 and 
a specific antibody can unbalance BCL-XL/BCL-XS, leading to depolarization of the 
mitochondrial membrane potential, with reduction of ATP and subsequent alteration of 
contractility (Force, 2007). 
2.5 Risk factors 
The most established risk factors for the development of trastuzumab-induced 
cardiotoxicity are age > 50 years and concurrent or prior exposure to anthracycline 
chemotherapy (Perez, 2004; Pinder, 2007). Based on data of the NSABP B-31 trial (Tan-Chiu, 
et al., 2005), baseline LVEF < 55% and  post-chemotherapy LVEF < 55% were also 
considered as significant risk factors. Current or previous treatment with antihypertensive 
medication and a body mass index (BMI) >25 have been shown to increase the risk of 
cardiotoxicity in some trials, but the results are not uniform or consistent. Prior radiotherapy 
to a left-sided breast cancer, race or history of smoking were not associated to a increased 
risk of cardiac toxicity during trastuzumab treatment.  
One important aspect is that clinical trials are limited to women under 65 years old and with a 
good performance status (Hutchins, 1999). Thus, trastuzumab safety data only apply to a 
relatively young and healthy group of patients. As the incidence of cancer increases greatly 
with age and more than 70% of all newly diagnosed cancers are in patients >65 years, 
information about efficacy and safety of chemotherapy is needed in this population. This was 
the impetus of a recent study by C. Serrano et al (Serrano, 2011) that intended to assess the 
cardiac safety profile and potential cardiac risk factors associated with trastuzumab in breast 
cancer patients >70 years. The records of forty-five women between the ages of 70 and 92 were 
evaluated and was found a significantly increased incidence of cardiac events among patients 
with a history of cardiac disease (heart failure, arrhythmias, myocardial ischemia, or valvular 
heart disease) and diabetes. The overall incidence of cardiac events was 26.7%, and in 8.9% of 
them it was clinically evident. Thirty-three percent of women with known history of heart 
disease developed either asymptomatic or symptomatic cardiotoxicity compared to 9.1% with 
no previous cardiac disease (p=0.01). Additionally, 33.3% of diabetic women developed 
cardiac dysfunction compared to only 6.1% without diabetes. However, it is important to be 
cautious when interpreting these data given the small sample size and the very limited power 
to detect small differences in multivariate analysis. 
In patients being simultaneous treated with anthracyclines and trastuzumab the probability 
of develop cardiotoxicity increases after a cumulative dose of doxorubicin superior to 300 
mg/m2 (Perez, 2004). The sequence in which chemotherapy agents are administered seem to 
influence the development of cardiac dysfunction. When anthracyclines and trastuzumab 
were administered simultaneously, the incidence of NYHA class III or IV HF was 16%. 
(Slamon, 2001). The interval between administration of anthracycline and trastuzumab was 
about 3 weeks in the NSABP B-31 and BCIRG 006 trials, and it was showed an incidence of 
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class III or IV CHF of 4.1% and 1.9%, respectively (Romond 2005). This interval was larger in 
HERA trial, being approximately 3 months, and was found an incidence of cardiac 
dysfunction of 0.6%, similar to that obtained in the nonanthracycline arm of the BCIRG 006 
trial (0.4%). (Piccart-Gebhart, 2005; Tan-Chiu, 2005; Joensuu, 2006) Thus, it seems that the 
greater the interval between treatment with these two drugs, the less cardiotoxicity is found. 
(Ewer, 2009) (Fig. 2)   
 
Reprinted from Nat. Rev Cardiovasc Med ©2010 Nature Publishing 
Fig. 2. Incidence of heart failure in the different trials in what concern timing post 
anthracycline treatment 
2.6 Clinical course  
Current data on trastuzumab-induced cardiomyopathy suggest that either symptomatic or 
asymptomatic LVEF decline has potential to recover by stopping the agent and introducing 
medical therapy for HF. 
In the CREC review (Seidman, 2002) of the 112 patients who developed cardiotoxicity, 79% 
responded to HF therapies. Further evidence of this phenomenon comes from MD 
Anderson series (Guarneri, 2006). In patients who developed symptomatic CHF, 79% 
recover after discontinuation of trastuzumab and with appropriate treatment. Of note, one 
patient recovered quickly with cardiac therapy during treatment with trastuzumab and one 
died of progressive CHF. 
In those patients with asymptomatic decline of LVEF, trastuzumab was stopped in 41%. 
Recovery of LVEF was observed in 89% of women, independently of HF treatment. For the 
remainder who continued trastuzumab, LVEF recovered in 75% of patients.  
Ewer et al (2005) published an observational study of 38 patients with trastuzumab-related 
cardiotoxicity. Thirty-one patients discontinued the agent and were treated with HF 
therapies. In all of them LVEF returned to baseline over a period of months (mean time: 1.5 
months). In six women who stopped trastuzumab, but were not receiving HF treatment, 2 
had persistent LV dysfunction during the 6 months follow-up. Trastuzumab was not 
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withdrawal in one patient, despite evidence of cardiotoxicity, and after initiation of HF 
therapy was demonstrated a slight increase of LVEF. In a subgroup of patients (Ewer, 2002) 
treated with the maximum-tolerated doses of angiotensin converting enzyme inhibitors and 
beta-blockers, which had a full recovery of LVEF and had stable CHF, trastuzumab was 
reintroduced. The median duration of trastuzumab therapy was 8.4 months. In 88% of 
women (Ewer, 2005) LVEF remained stable and without recurrences of CHF; in the 
remainder, LVEF deteriorated and CHF reoccurred, necessitating permanent trastuzumab 
withdrawal. (Fig. 3) None of the patients died due to cardiac disease, and only one patient 
needed to be hospitalized because of CHF with volume overload.  
 
Reprinted from Ewer et al. (2005) Reversibility of trastuzumab related cardiotoxicity: new insights 
based on clinical course and response to medical treatment. Journal of Clinical Oncology, Vol. 23, pp. 
7820–7826 
Fig. 3. Changes in left ventricular ejection fraction from baseline to re-treatment with 
trastuzumab (*) P<0.05 versus before trastuzumab therapy. (+) P<0.05 versus after 
trastuzumab therapy.  
Similar results were obtained in trastuzumab adjuvant trials. In B-31 (Tan-Chiu et al. 2005) 
the majority of patients who developed cardiac dysfunction recovered completely (55.5%) or 
partially (30.6%), as in HERA trial (Piccart-Gebhart, 2005) were there was 81% of recovery.  
Although current data is limited regarding the potential long-term effects of trastuzumab on 
cardiac function, actual evidence of trastuzumab-induced cardiotoxicity should be 
evaluated in the context of the improvements in disease-free survival, response rate and 
quality of life attributable to trastuzumab therapy. (Table 5) Thus efforts should be placed 
on close cardiac function monitoring and development of strategies to early diagnosis. 
2.7 Monitoring of cardiotoxicity 
Outside the trials, the best cardiac monitoring strategy remains undefined. The British Society 
of Echocardiography (Fox, 2006) and more recently the European Society for Medical 
Oncology (Bovelli et al., 2010), issued a statement regarding the cardiac monitoring of patients 
proposed to receive trastuzumab. Clinical evaluation and assessment of cardiovascular risk 
factors and comorbidities should be performed to all women prior the initiation of this agent. 
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Reprinted from Patrick G. et al (2010). Trastuzumab-Related Cardiotoxicity Following Anthracycline-
Based Adjuvant chemotherapy: How Worried Should We Be? Journal of Clinical Oncology, Vol 28 , No. 
21, pp 3407-3410 
Table 5. Long-term cardiac risk.benefit analysis of trastuzumab-based adjuvant 
chemotherapy.  
The statements specified that LV function must be assessed before treatment and at 3-month 
intervals during the administration of trastuzumab.  
Echocardiography is the recommended method for evaluating LV function. (Bovelli et al., 
2010) Among the imaging techniques, echocardiography has multiple advantages as it is 
easily accessible, with no radiation exposure and can assess LV systolic and diastolic 
dysfunction, heart valve disease, pericarditis and pericardial effusion.  
LVEF is the most frequent parameter used for evaluation of cardiac function before 
initiating chemotherapy and a value less than 54% is considered a risk factor for subsequent 
development of HF. Extreme caution during consecutive assessment of LVEF is 
fundamental, in order to diminish the intra and interobserver variability. The use of 3-
dimensional echocardiography or administration of contrast for left ventricle opacification 
can be useful strategies to achieve this proposal. However, LVEF is not a sensitive index to 
detect early systolic cardiac dysfunction. (Bovelli et al., 2010) Other echocardiographic 
techniques such as Doppler-derived parameters seem to show early changes in myocardial 
function in this setting. (Hare, 2009; Fallah-Rad, 2008). 
Myocardial scintigraphy provides a very reliable measurement of LVEF, however does not 
allow evaluation of regional myocardial kinetic or diastolic function, which can be important 
aspects of cardiotoxicity. Additionally, it has the disadvantage of radiation exposure. 
Cardiac magnetic resonance imaging (MRI) is the gold standard for accurate assessment of 
LV volumes and LVEF, and also allows evaluation of myocardial perfusion and tissue 
characterization. The common feature of trastuzumab-induced cardiotoxicity is increase of 
LV volumes, decrease in LVEF and delayed enhancement within the mid-myocardium 
portion of LV (Fallah-Rad et al., 2008). MRI has already been validated for LV function 
monitoring in patients treated with trastuzumab, however, due to its high cost and limited 
availability, it can not be used as screening test.  
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In this field, for an accurate monitoring oncologists and cardiologists should work as a team 
and prompt multidisciplinary approach to patient care, in order to detect damage caused by 
chemotherapy and achieve a positive resolution. 
2.8 Importance of early diagnosis of trastuzumab-related cardiotoxicity 
Identification of patients who will develop heart failure as a result of trastuzumab treatment 
remains an ongoing challenge. Currently, clinical examination and consecutive LVEF 
measurements have been used to determine the cardiac toxicity of chemotherapy. However, 
it has important limitations, namely the fact that a decline of LVEF represents a relatively 
late stage of cardiac dysfunction. Earlier detection of subclinical cardiac damage could lead 
to identifying, intervening, and possibly preventing late adverse cardiac outcomes. In the 
setting of trastuzumab-induced cardiotoxicity, it could allow to identify patients at higher 
risk that could benefit from prophylactic therapy, and also identify those who may recover 
from cardiac dysfunction and thus, not discontinued indiscriminately trastuzumab therapy 
depriving most patients from drug’s effectiveness. 
There is an intense research in this area, especially in what concern the role of cardiac 
biomarkers and new echocardiographic techniques. 
2.8.1 The role of new echocardiographic techniques 
Two dimensional evaluation of LVEF constitutes the most common way to assess cardiac 
function in chemotherapy-induced cardiomyopathy, but it has some limitations, namely low 
reproducibility and dependence of hemodynamic conditions. 
Myocardial strain and strain rate (SR) are newer echocardiographic techniques for 
evaluation of LV function, offering sensitive measurement of myocardial deformation, and 
seem to be able to identify subclinical dysfunction in various settings, before impairment of 
LVEF becomes evident. (Geyer et al., 2010). These parameters can be assessed by tissue 
Doppler imaging (TDI) or more recently, by speckle tracking (ST).  
TDI uses Doppler principles to quantify tissue-derived signals, enabling a quantitative 
analysis of systo-diastolic function in terms of global, regional, segmental and parietal 
function. Strain and SR assessed by TDI are pulsed Doppler measurements with spatial 
integration, obtained by determination of myocardial parietal displacement, taking into 
account the linear distance between the two points. (Ho & Solomon, 2006). 
Speckle tracking is a distinct method to evaluate global and regional LV function. It’s not 
Doppler based and thus, allow assessment of strain and SR independently of angle, a 
limitation of TDI. An important feature of this technique is the possibility of assessing 
longitudinal, radial and circumferential LV deformation in a single acquisition. 
Additionally, it is simple to perform, the processing can be done subsequently offline and 
has a reduced intra and interobserver variability (Geyer et al., 2010). 
These echocardiographic techniques have been evaluated in murine models of 
chemotherapy-related cardiotoxicity and more recently, in patients with anthracycline-
induced cardiomyopathy. (Neilan et al, 2006; Jassal et al, 2009)  
Recently some research has been done to elucidate the role of these imaging techniques in 
subclinical detection of trastuzumab-induced cardiotoxicity. 
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Hare et al. (2009) studied 35 women treated with trastuzumab in the adjuvant and 
metastatic setting. LVEF measured either by 2D and 3D echocardiography, as well as 
myocardial E-velocity, did not demonstrate significant change in the patients evaluated. 
However, a reduction in longitudinal SR at 3 months after trastuzumab administration was 
detected in 18 patients. (Fig. 4) Three of them had a subsequent decrease in LVEF and 
another 2 patients showed a decline in LVEF within 20 months of follow-up. Data from this 
study suggest SR to be a parameter able to identify early impairment of cardiac function in 
trastuzumab-induced cardiomyopathy setting. 
 
Reprinted from Hare, J. et al (2009). Natasha Woodward, Thomas H. Marwick Use of myocardial 
deformation imaging to detect preclinical myocardial dysfunction before conventional measures in 
patients undergoing breast cancer treatment with trastuzumab. American Heart Journal, Vol. 158, No. 2, 
pp. 294-301 
Fig. 4. Example of preclinical reduction in myocardial deformation. Reductions in TDI SR and 
2D speckle-tracking strain from initial echocardiogram (A) over 2 months during therapy with 
trastuzumab (B), with no concomitant reduction in 3D LVEF in a patient who ceased 
trastuzumab for symptoms consistent with myocardial dysfunction. GS, Global strain.  
The study published by Fallah et al. (2011) showed similar results. Indeed it was found that 
an early reduction in TDI and strain values was subsequently followed by a significant 
decline of LVEF. Forty two patients were studied and 10 of them developed cardiac 
dysfunction, necessitating withdrawal of trastuzumab. There weren’t significant differences 
in baseline TDI and strain parameters between patients who developed cardiotoxicity and 
those who maintain normal LVEF measurements. However, at 3 months after initiation of 
therapy was found a significant decrease in lateral S’ value in patients who developed 
cardiac dysfunction, as well as a reduction in peak global longitudinal and radial strain. 
Although LVEF was normal at 3 months, TDI and strain measurements were reduced in all 
10 patients who demonstrated an impairment of LVEF at 6 months follow up. 
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A possible explanation for the increased sensitivity of strain in early detection of 
chemotherapy-induce cardiotoxicity can be a preferential regional pattern of damage, such 
that normal myocardial segments compensate the impaired function of the other, leading to 
a preserved LVEF. 
TDI and speckle tracking imaging are thus, very promissory tools for early detection of LV 
systolic dysfunction in trastuzumab treated patients.  
2.8.2 The role of biomarkers 
Troponin I (TNI) has high sensibility and specificity to detect myocardial ischemia. Raised 
levels have been found after anthracycline administration and seem to predict subsequent 
cardiac morbidity and mortality. Indeed, Cardinale et al. 2004) showed that detectable TNI 
after high-dose chemotherapy is a predictor of LVEF impairment and higher rate of major 
cardiac events, especially in women who maintain elevation of TNI for more than a month 
(Fig.5). 
In addition, they reported a high negative predictive value for TNI (99%), which is important 
to identify low-risk patients who probably don’t need close monitoring after treatment. 
 
Reprinted from Cardinale, D. et al. (2004). Prognostic Value of Troponin I in Cardiac Risk Stratification 
of Cancer Patients Undergoing High-Dose Chemotherapy. Circulation, Vol. 109, pp. 2749-2754 
Fig. 5. Cumulative cardiac events rate in 3 study groups. P<0.001 for TnI +/+ vs TnI-/- and 
TnI+/-, and for TnI +/- vs TnI-/-.  
The role of TNI in the clinical setting of trastuzumab-induced cardiotoxicity was recently 
assessed by Cardinale et al. (2010). A substantial finding of the study was that TNI 
assessment permits to detect patients more likely to developed LVEF impairment and to 
identify those who are less prone to recover. Indeed, trastuzumab-induced cardiotoxicity 
was detected in 72% of those who had elevation of TNI and in 7% of patients with normal 
TNI. From those who developed cardiac dysfunction, 60% recovered. The patients, whom 
LVEF did not return to baseline values had previous elevation of TNI, and additionally was 
found that this subgroup had a higher rate of cardiac events along the follow up (Fig.6). 
Interestingly, in those women with normal TNI who developed trastuzumab-related 
cardiotoxicity, was observed a subsequent normalization of LVEF and a lower rate of major 
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cardiac events. These data are consistent with the hypothesis that a normal TNI value can 
predict LVEF recovery. 
Additionally, the rate of major cardiac events, and thus increased morbidity, was higher in 
the patients who showed elevation of TNI.  
Can be inferred that TNI permit to divide patients in two subgroups: those with good 
outcome, from those more prone to adverse events in whom close surveillance and 
prevention of further cardiotoxicity is needed. 
 
Reprinted from: Cardinale et al. (2010). Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic 
Implications of Troponin I Evaluation. Journal of Clinical Oncology, Vol. 28, No. 25, pp. 3910-3916 
Fig. 6. (A) Kaplan-Meier curve of time to first cardiac event in patients developing 
trastuzumab-induced cardiotoxicity (TIC) and in patients who did not (No TIC). (B) 
Cumulative major adverse cardiac events in patients who recovered from cardiac 
dysfunction (Recovery) and in those who did not (No-recovery). Time zero refers to 
detection of cardiotoxicity and start of heart failure (HF) therapy. 
Other studies such as the one published by Sawaya et al. (2011) showed similar results. 
Indeed an elevated TNI at three months predicted cardiac dysfunction at six months, as 
these patients were nine times more prone to developed cardiotoxicity than those with 
normal TNI values. 
B-type natriuretic peptide (BNP) is a marker of increased filling pressure of LV, as it is a 
hormone released by myocardial cells in volume overload setting. An important feature is 
that it can be detectable in a subclinical stage of HF and its value reflects HF severity. 
(Emdin et al., 2005)  
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Thus it seemed reasonable to assume that BNP would be increased in patients with 
chemotherapy-induced cardiomyopathy. However, data currently available are 
heterogeneous. Some studies reported an elevation of BNP after treatment (Sandri et al., 2005; 
Pinchon et al., 2005), others obtained negative results (Sawaya et al., 2011). Therefore, the 
utility of BNP as a biomarker of cardiac damage induced by chemotherapy was not confirmed.  
Larger, prospective trials are needed to elucidate BNP role in this setting. 
3. Treatment and prevention strategies 
Guidelines suggest HF standard therapy in patients with symptomatic or asymptomatic 
evidence of trastuzumab-induced cardiac dysfunction. However, as these patients have 
been excluded from almost all large randomized trials assessing the efficacy of HF 
treatment, there isn’t definite evidence whether the long-term benefits of HF therapy can be 
directly transferred to this setting  (Bovelli, 2010; Eschenhagen, 2011).  
Nevertheless, data from adjuvant trials of trastuzumab and observational studies, such as 
the one conducted by Ewer et al (2005), support the use of HF therapy specially angiotensin 
converting enzyme inhibitors (ACEI) and beta-blockers.  
Some other questions in this setting need to be addressed. Should we withdraw 
trastuzumab in patients who developed cardiotoxicity independently of the grade of LVEF 
impairment? Some authors proposed an evaluation scheme showed in Table 6, in which 
trastuzumab should be stopped in asymptomatic patients if LVEF declines more than 20 
points from baseline or LVEF<30%, and in symptomatic patients if LVEF reduces more than 
30 points from baseline. And should we discontinue the drug in all patients who developed 
cardiotoxicity or just in high-risk patients? Based on results of the study by Cardinale et al. 
(2010) we can speculate that patients with normal value of TNI and reduction in LVEF could 
be maintained in trastuzumab therapy while receiving HF therapy and close monitoring. 
However we don’t have yet a definite answer. Another important issue is, should we treat 
prophylactically high-risk patients? The data from Cardinale et al. (2006) suggest that early 
treatment with enalapril in patients with TNI positive after high-dose chemotherapy, 
prevent the development of cardiac dysfunction. (Fig. 7) Indeed, in those patients treated 
with ACEI, LVEF remained normal and compared with the untreated patients, a lower rate 
of adverse cardiac events was seen. (Table 6) 
 
Reprinted from Cardinale, D. et al. (2006). Prevention of high-dose chemotherapy-induced 
cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation, Vol. 114, 
pp. 2474-2481 
Table 6. Cardiac events in the study groups 
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Reprinted from Cardinale, D. et al. (2006). Prevention of high-dose chemotherapy-induced 
cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation, Vol. 114, 
pp. 2474-2481 
Fig. 7. Patients showing increased TNI value during follow-up in the ACEI group (open 
bars) and control subjects (solid bars). P<0.001 (log-rank test). Mean ± SD TNI values at each 
considered step are given at the bottom. *P<0.05 vs ACEI group. 
Kalay et al. (2006) studied the impact of prophylactic carvedilol use in patients receiving 
anthracycline chemotherapy and showed that LVEF maintained stable in those treated with 
beta-blocker, contrary to what occurred in the untreated group.  
Probably the MANTICORE - Multidisciplinary Approach to Novel Therapies In Cardiology 
Oncology Research - trial, will add some light to this issue. This is a randomized, placebo-
controlled trial that aims to determine if standard HF therapies can prevent trastuzumab-
induced cardiotoxicity. (Pituskin, 2011) 
 
Adapted from Keefe DL. (2002). Trastuzumab-associated cardiotoxicity. Cancer, Vol. 95, pp. 1592-1600  
↓=decrease; B=beta-blockers; CF=cardiac failure; LVEF=left ventricular ejection fraction; 
NC=noncardiac pathology. trastuzumab 
Table 7. Proposal for the evaluation and treatment of heart failure in patients undergoin 
treatment with trastuzuma 
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Some authors suggest other strategies to minimize cardiotoxicity (Sengupta, 2008), such as 
the adoption of non-anthracyclines regimes, to prefer larger intervals between the 
administration of anthracyclines and trastuzumab or to diminish the duration of 
trastuzumab adjuvant therapy. However, our conviction is that we should prompt effort in 
early diagnosis of cardiac dysfunction and appropriate treatment, in order to not deprive 
patients to a treatment with such substantial therapeutic benefits and propose the algorithm 
presented in Figure 8, for the management of patients receiving trastuzumab. 
  
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; 
ECG, electrocardiography; HF, heart failure; LVEF, left ventricular ejection fraction (adapted from 
Martin M et al (2009);  
Fig. 8. Proposed algorithm for the management of patients receiving treatment with 
trastuzumab.  
4. Conclusion 
Trastuzumab is the standard of care for treatment of patients with ERB2-positive breast 
cancer. When used in combination with chemotherapy, trastuzumab can improve overall 
survival in patients with ERB2-positive metastatic breast cancer and disease free survival 
and overall survival in patients with early ERB2-positive breast cancer. Because of the risk of 
cardiac dysfunction associated with trastuzumab therapy, cardiac function should be 
monitored closely (Carver, 2010). 
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Cardiotoxicity has a strong impact on patients with cancer. This paradigm suggests that a 
multidisciplinar team of cardiologists and oncologists may provide a more comprehensive 
care to this complex patient population.  
The main strategy is early detection of high risk patients and prompt prophylatic treatment. 
New echocardiographic methods to detect subclinical myocardial changes, measurement of 
cardiospecific biomarkers may become useful routine methods for identifying patients more 
prone to developing cardiotoxicity and in whom a preventive pharmacologic approach 
together with a closer cardiac monitoring could reduce a major cause of mortality in women 
with breast cancer. 
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